Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design.
The aim of this work was to investigate the effects of formulation variables on development of carvedilol (CAR) proniosomal gel formulations as potential transdermal delivery systems. Different non-ionic surfactants; polyoxyethylene alkyl ethers, namely Brij 78, Brij 92, and Brij 72; and sorbitan fatty acid esters (Span 60) were evaluated for their applicability in preparation of CAR proniosomal gels. A 2(3) full factorial design was employed to evaluate individual and combined effects of formulation variables, namely cholesterol content, weight of proniosomes, and amount of CAR added on performance of proniosomes. Prepared proniosomes were evaluated regarding entrapment efficiency (EE%), vesicle size, and microscopic examination. Also, CAR release through cellulose membrane and permeation through hairless mice skin were investigated. Proniosomes prepared with Brij 72 and Span 60 showed better niosome forming ability and higher EE% than those prepared with Brij 78 and Brij 92. Higher EE% was obtained by increasing both weight of proniosomes and amount of CAR added, and decreasing cholesterol content. Release rate through cellulose membrane was inversely affected by weight of proniosomes. In Span 60 proniosomes, on increasing percent of cholesterol, a decrease in release rate was observed. While in Brij 72 proniosomes, an enhancement in release rate was observed on increasing amount of CAR added. Permeation experiments showed that skin permeation was mainly affected by weight of proniosomes and that Span 60 proniosomal gels showed higher permeation enhancing effect than Brij 72. Proniosomal gel could constitute a promising approach for transdermal delivery of CAR.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, 11562, Cairo, Egypt. aaboelwafa@hotmail.com
Ahmed A
AA
Aboelwafa
Doaa Ahmed
DA
El-Setouhy
Aliaa Nabil
AN
Elmeshad
D000279:Administration, Cutaneous; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D002227:Carbazoles / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D000077261:Carvedilol; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005227:Fatty Acids; D005782:Gels; D006601:Hexoses / Q000737:chemistry*; D008081:Liposomes; D051379:Mice; D010539:Permeability; D011092:Polyethylene Glycols / Q000737:chemistry*; D011412:Propanolamines / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D012107:Research Design; D012867:Skin; D012869:Skin Absorption; D013501:Surface-Active Agents
D000959:Antihypertensive Agents; D002227:Carbazoles; D005227:Fatty Acids; D005782:Gels; D006601:Hexoses; D008081:Liposomes; D011412:Propanolamines; C495681:Sanonic SS-90; D013501:Surface-Active Agents; D000077261:Carvedilol; D011092:Polyethylene Glycols; C009298:sorbitan monostearate